topic

294 Comparison of preclinical efficacy between CD19 CAR-T and CD3×CD19 bispecific antibody (blinatumomab)
Xiangnan Qiang, Ronghua Zhang, Zhixiang Zhang, Chenhui He, Zhifeng Zhao, Jingwei Huang, Ting Ni, Jun Huang, Xiangyi Wang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A335; DOI: 10.1136/jitc-2023-SITC2023.0294
295 Novel T-cell immunotherapeutics enable the selective generation of more potently cytotoxic CD19 chimeric antigen receptor T-cells (CAR-T cells) from CMV-specific cytotoxic T-cells
Moriah Rabin, Erin Cole, Scott Garforth, Jian Hua Zheng, Steven Almo, Harris Goldstein

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A336-A338; DOI: 10.1136/jitc-2023-SITC2023.0295
296 HER2-specific highly scalable CAR NK cell (anti-HER2-CAR SNK02) exhibits a significantly enhanced antitumor activity against HER2-expressing tumors as an off-the-shelf allogeneic immune cell therapy
Yong-hee Rhee, Hee-Sung Chae, Minji Kim, Seo-Gu Kang, Joungmin Lee, Yoon Mi Kang, Jae Seob Jung, Paul Y Song, Yong Man Kim, Minchan Gil

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A339; DOI: 10.1136/jitc-2023-SITC2023.0296
297 Improvement of CAR T-cell performance by simultaneous downregulation of multiple co-inhibitory receptors
Matteo Rossi, Fanny Huberty, Thuy Nguyen, Jerome Marijsse, Celine Jacques-Hespel, Eytan Breman

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A340; DOI: 10.1136/jitc-2023-SITC2023.0297
298 A miRNA-based shRNA platform for the easy, safe, and effective generation of allogeneic CAR T-cells
Matteo Rossi, Fanny Huberty, Jerome Marijsse, Thuy Nguyen, Celine Jacques-Hespel, Eytan Breman

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A341; DOI: 10.1136/jitc-2023-SITC2023.0298
299 SNAP CAR T cells for programmable antigen targeting
Elisa Ruffo, Victor So, Michael Kvorjak, Olivera J Finn, Alexander Deiters, Jason Lohmueller

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A342; DOI: 10.1136/jitc-2023-SITC2023.0299
300 Transcriptional engineering of CAR T cell memory promotes durable control and synergy with PD-1 checkpoint blockade immunotherapy in solid tumors
Surojit Sarkar, Jim Reed, Samantha Tower, Asheema Khanna, Vandana Kalia

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A343; DOI: 10.1136/jitc-2023-SITC2023.0300
301 Preclinical development of AB-2100, a PSMA neovasculature-inducible CA9 CAR resistant to FASL and TGFb mediated suppression for the treatment of ccRCC
Irene Scarfo, Laura Lim, Kevin Dang, Marvin Chew, Rakesh Sudhakah, Michelle Nguyen, Suchismita Mohanty, Jeremy Chen, Alma Gomez, Nickolas Attanasio, Amanda Fearon, Ivan Chan, Vibhavari Sail, Thomas J Gardner, Beatriz Millare, James Zhang, Darrian Moskowitz, Vince Thomas, Stanley Zhou, Jenessa Smith, Jennifer McDevitt, Angela Boroughs

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A344; DOI: 10.1136/jitc-2023-SITC2023.0301
302 Generation of immune-evasive allogeneic CAR T cells by inactivation of the HLA transcriptional regulator RFX5 and disruption of the immune synapse
Tanu Shenoy, George Nguyen, Ki Eun Pyo, Barbra Sasu, Hsinyuan Cheng, Cesar Sommer

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A345; DOI: 10.1136/jitc-2023-SITC2023.0302
303 PiggyBac transposon-mediated HER2-CAR-T cells exert anti-tumor efficacy against cholangiocarcinoma
Koichiro Shioya, Motoya Mie, Yuji Mishima, Tomio Matsumura, Yuta Ohira, Miyuki Tanaka, Shigeki Yagyu, Yozo Nakazawa, Lilin Zhang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A346; DOI: 10.1136/jitc-2023-SITC2023.0303

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages